| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Frizzled-7, Fz-7, hFz7, FzE3, FZD7 |
| Entrez GeneID | 8324 |
| WB Predicted band size | 63.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This FZD7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 202-229 amino acids from the Central region of human FZD7. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FZD7抗体的示例参考文献(注：以下为假设性示例，具体文献需通过学术数据库核实)：
1. **"Targeting FZD7 with a novel monoclonal antibody inhibits Wnt signaling in colorectal cancer models"**
*作者：Smith A, et al.*
摘要：研究报道了一种新型抗FZD7单克隆抗体的开发，该抗体通过阻断Wnt/β-catenin信号通路，在结直肠癌小鼠模型中显著抑制肿瘤生长并减少转移。
2. **"FZD7 antibody-mediated inhibition of cancer stem cell self-renewal in triple-negative breast cancer"**
*作者：Chen L, et al.*
摘要：本文验证了抗FZD7抗体通过下调Wnt信号通路关键蛋白，抑制三阴性乳腺癌干细胞的自我更新能力，为靶向肿瘤干细胞治疗提供实验依据。
3. **"Structural characterization of a humanized FZD7 antibody and its therapeutic potential in hepatocellular carcinoma"**
*作者：Wang Y, et al.*
摘要：研究解析了人源化FZD7抗体的结构特征，并证明其在肝癌细胞系和患者来源异种移植模型(PDX)中可诱导肿瘤细胞凋亡，且耐受性良好。
4. **"FZD7 as a diagnostic biomarker: Development of a high-affinity antibody for serum detection in pancreatic cancer"**
*作者：Kim H, et al.*
摘要：开发了一种高亲和力抗FZD7抗体，用于检测胰腺癌患者血清中的FZD7外泌体水平，显示其作为早期诊断生物标志物的潜力。
建议通过PubMed、Web of Science或Google Scholar检索关键词“FZD7 antibody”、“anti-FZD7 therapy”等获取真实文献。
FZD7 (Frizzled-7) antibody targets the Frizzled-7 receptor, a key component of the Wnt signaling pathway, which plays critical roles in embryonic development, tissue homeostasis, and stem cell regulation. As a member of the Frizzled family of G protein-coupled receptors, FZD7 binds Wnt ligands to activate both canonical (β-catenin-dependent) and non-canonical Wnt signaling pathways. Dysregulation of FZD7 is implicated in various cancers, including colorectal, breast, and hepatocellular carcinomas, where it promotes tumor proliferation, invasion, and chemoresistance.
FZD7 antibodies, often monoclonal, are designed to inhibit receptor function by blocking Wnt-FZD7 interactions or downregulating receptor expression. These antibodies have emerged as potential therapeutic tools in oncology, particularly for targeting cancer stem cells (CSCs) that rely on Wnt signaling for self-renewal. Preclinical studies highlight their ability to suppress tumor growth and metastasis in models of triple-negative breast cancer and other malignancies. Additionally, FZD7 antibodies serve as valuable research reagents for studying Wnt pathway mechanisms, tissue regeneration, and developmental biology. Challenges remain in optimizing specificity and minimizing off-target effects, but ongoing research aims to advance their clinical translation for precision cancer therapies.
×
